{"id":9658,"date":"2021-07-11T21:15:17","date_gmt":"2021-07-12T02:15:17","guid":{"rendered":"https:\/\/ionicalliance.com\/?p=9658"},"modified":"2021-07-13T16:49:20","modified_gmt":"2021-07-13T21:49:20","slug":"preclinical-anticancer-efficacy-studies-on-ibal-formulations","status":"publish","type":"post","link":"https:\/\/ionicalliance.com\/preclinical-anticancer-efficacy-studies-on-ibal-formulations\/","title":{"rendered":"Preclinical Anticancer Efficacy Studies on IBAL Formulations"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Preliminary Evaluation Of ION-ZC1 As A Potential Anticancer Agent In Vitro<\/h4>\n\n\n\n<ul><li>Completed in 2018 by Brooklyn College and The City University of New York, USA.<\/li><li>The ION-ZC1 solution is a responsive cytotoxic agent against:<ul><li>Renal carcinoma cell line Caki-1 (IC50 36.12 \u00b1 1.00 \u03bcM),<\/li><li>Triple-Negative Breast Cancer (MDA-MB-231),<\/li><li>and Melanoma cancer cell line A375 (IC50 95.20 \u00b1 1.01 \u03bcM)<\/li><\/ul><\/li><li>Highly selective when compared to the cytotoxicity of ION-ZC1 on control cells IMR-90 (IC50 142.6 \u00b1 6.65 \u03bcM).<\/li><li>The ION-ZC1 solution induces apoptotic death in 92% of renal carcinoma cell line Caki-1 at dose IC50 36.12 \u00b1 1.00 \u03bcM.<\/li><\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">ION-ZC1 Topical Cream Anti-Tumor Efficacy Study Using A Syngeneic Mouse Melanoma Model (B16F0 \u2013 C57BL\/6J), Study Design Of 30 Mice.<\/h4>\n\n\n\n<ul><li>Completed in 2017 by the University of Debrecen, Hungary.<\/li><li>The main conclusion drawn from the study is that ION-ZC1 Topical Cream (17%) is:<ul><li>Significantly efficacious against metastatic mouse melanoma as tested in a subcutaneous syngeneic mouse model (B16-F0 in C57BL\/6J mice).<\/li><li>More efficacious than the Imiquimod Topical Cream (5%).<\/li><li>Tumor volumes recorded over the treatment period in the three groups support that tumor growth was slower as inhibited by ION-ZC1 Topical Cream (17%), and its effect was more pronounced as compared to the inhibitory effect of ALDARA (5% Imiquimod) Positive Control substance on tumor growth.<\/li><\/ul><\/li><li>Conclusively, ION-ZC1 Topical Cream (17%) treatment extended survival time.<\/li><\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">ION-ZC1 Anti-Tumor Efficacy Study By Intravenous Injection (Parenteral) Route, Using A Syngeneic Mouse Xenograft Model, More Specifically A Subcutaneous B16 Mouse Melanoma Model In C57BL\/6J, Study Design Of 30 Mice.<\/h4>\n\n\n\n<ul><li>Completed in 2016 by the University of Debrecen, Hungary.<\/li><li>Safety abnormalities compared to control tumor mice were not noted for any of the animals when necropsied at the conclusion of the 14-day observation period. As the most important results from the histopathological analysis, we can state that:<ul><li>Tumors isolated from mice treated with various concentrations of ION-ZC1 IV injections show massive necrosis, which is not pronounced as much in tumors isolated from control tumor mice;<\/li><li>Blood vessels are much less frequent, less developed in the ION-ZC1 treated mice compared to control tumor mice.<\/li><li>ION-ZC1 injection results in spleen enlargement, which is remarkably (2-3 times) bigger in extent than that of the spleen of control (untreated) tumor mice, and consistent with ION-ZC1 inducing a strong anti-tumor immune response.<\/li><\/ul><\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/ionicalliance.com\/wp-content\/uploads\/2019\/08\/ceidr-banner-1024x1024.jpg\" alt=\"Preclinical Anticancer Efficacy Studies On IBAL Formulations\" class=\"wp-image-8714\" width=\"1138\" height=\"1138\" srcset=\"https:\/\/ionicalliance.com\/wp-content\/uploads\/2019\/08\/ceidr-banner-1024x1024.jpg 1024w, https:\/\/ionicalliance.com\/wp-content\/uploads\/2019\/08\/ceidr-banner-150x150.jpg 150w\" sizes=\"(max-width: 1138px) 100vw, 1138px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Preliminary Evaluation Of ION-ZC1 As A Potential Anticancer Agent In Vitro Completed in 2018 by Brooklyn [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":9846,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[22,58,64,57,19,59],"tags":[],"_links":{"self":[{"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/posts\/9658"}],"collection":[{"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/comments?post=9658"}],"version-history":[{"count":0,"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/posts\/9658\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/media?parent=9658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/categories?post=9658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ionicalliance.com\/wp-json\/wp\/v2\/tags?post=9658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}